In $KAST , we are dealing with a tiny float play in the biotech space. The company has a new deal in formation with a top-tier player to fund and attack areas in the biopharma space that offer the best ROI upon approach. This is every bit the nimble opportunist. That’s a plus for investors. http://www.stockonhighalert.com/newsletters/kast-offers-tactical-opportunity-strong-biopharma-trend/